Generated June 18, 2026 at 10:39 AM ET
· Covers June 18 trading day
· 10 of 67 ready 8-Ks selected
· AI-assisted overview
Hugoton Royalty Trust declared no June distribution and cited going concern doubts, while Dyadic received a Nasdaq delisting notice for bid price and continued listing deficiencies. BioForce Nanosciences changed control via a 79.65% stake sale and pivoted to oil & gas, and Pfizer announced its CFO will step down in August. Ondas agreed to acquire Cyberhawk for ~$125M, Deluxe to acquire Celero Commerce for $625M, and Janus Henderson's take-private is set to close June 30. NovoCure reported its Phase 3 TRIDENT trial failed to show a survival benefit, and Steel Dynamics guided Q2 2026 EPS above prior periods. Cadrenal plans to file for FDA Rare Pediatric Disease Designation for tecarfarin in Kawasaki disease.
leadership
neutral
materiality 0.65
June 18, 2026, 7:07 AM ET
Pfizer CFO Dave Denton to step down Aug 15; Cecile Guegan named interim CFO
- Dave Denton to step down as CFO effective August 15, 2026, for a consumer goods opportunity.
- Departure not related to Pfizer's financial or operating results or any disagreements.
- Cecile Guegan, SVP Finance, Global Biopharm Business, named interim CFO effective August 16.
DYAI
DYADIC INTERNATIONAL INC
regulatory
negative
materiality 0.85
June 18, 2026, 9:55 AM ET
Dyadic receives Nasdaq delisting notice for bid price and continued listing deficiencies
- Nasdaq notified Dyadic on June 18, 2026 of failure to maintain minimum $1.00 bid price and meet continued listing standards.
- Company had until June 17, 2026 to cure bid price deficiency; did not comply and also lacked $5M equity for extension.
- Continued listing standards require $2.5M equity, $35M market value, or $500K net income; Dyadic fails all.
M&A
positive
materiality 0.85
June 18, 2026, 8:38 AM ET
Ondas to acquire Cyberhawk for ~$125M in cash; expands into critical infrastructure intelligence
- Transaction valued at ~$125M, ~95% cash funded; expected close in Q3 2026.
- Cyberhawk forecasted revenue >$45M for FY ending March 2027, ~95% recurring, $95M backlog.
- Cyberhawk brings 300+ customers, 500K+ assets inspected, 232 TB proprietary data, operations in 40 countries.
CVKD
Cadrenal Therapeutics, Inc.
regulatory
positive
materiality 0.65
June 18, 2026, 9:02 AM ET
Cadrenal to file for FDA Rare Pediatric Disease Designation for tecarfarin in Kawasaki
- Plans to submit RPDD request to FDA for tecarfarin to treat pediatric Kawasaki disease patients with coronary artery aneurysms.
- If RPDD granted and tecarfarin approved, eligible for Priority Review Voucher valued ~$200M (recent sales $180M-$205M).
- Dual-track strategy: Global Pharma (CAD-1005, Phase 3-ready for HIT) and Rare Disease (tecarfarin for Kawasaki).
M&A
positive
materiality 0.85
June 18, 2026, 7:11 AM ET
Deluxe to acquire Celero Commerce for $625M cash; expects Q3 2026 close
- All-cash deal for $625M plus seller expenses; financed via $375M Term Loan A and revolver draw.
- Expected to be accretive to adjusted EPS in first year post-close; cost synergies >$15M by 2028.
- Combined net leverage ~3.9x at close; target below 3.0x within 24 months; dividend policy unchanged.
JHG
JANUS HENDERSON GROUP PLC
M&A
neutral
materiality 0.80
June 18, 2026, 8:44 AM ET
Janus Henderson take-private with Trian/General Catalyst to close June 30, 2026; regulatory approvals secured
- Side letter sets closing date of June 30, 2026; termination date extended to September 20, 2026.
- All required regulatory approvals and client consents received for the $52.00/share cash take-private.
- Shareholders approved the merger on April 16, 2026; shares to be delisted from NYSE upon closing.
HGTXU
HUGOTON ROYALTY TRUST
other material
negative
materiality 0.90
June 18, 2026, 9:49 AM ET
Hugoton Royalty Trust declares no June distribution; going concern doubts persist
- No cash distribution for June 2026; no distributions since July 2023 due to excess costs on all three conveyances.
- Cumulative excess costs: Kansas $3.193M, Oklahoma $14.176M, Wyoming $11.582M (including accrued interest).
- Trustee has deferred its fee since April 2024; financing unlikely; considering termination or sale of assets.
BFNH
BIOFORCE NANOSCIENCES HOLDINGS, INC.
other material
neutral
materiality 0.90
June 18, 2026, 8:28 AM ET
BioForce Nanosciences changes control; sells 79.65% stake; pivots to oil & gas
- Merle Ferguson sold 26.7M shares (79.65% of outstanding) to Nexus Capital Investments for $400,000 on April 15, 2026.
- Co-CEOs Steven Gagnon and John LaViolette, and VP Sasha Shapiro resigned effective June 17, 2026.
- Scott Mager appointed as Director effective June 15, 2026; Richard Kaiser named interim CEO.
other material
negative
materiality 0.85
June 18, 2026, 7:00 AM ET
Novocure Phase 3 TRIDENT trial fails to show survival benefit for early TTFields in GBM
- Median OS 17.7 mo (Early Start) vs 17.5 mo (Maintenance Start); HR 0.953, p=0.519.
- 981 patients enrolled; 25% did not initiate maintenance phase across both arms.
- 1-/2-/3-year survival rates: Early Start 70.9%/33.9%/22.5%; Maintenance 72.0%/31.6%/18.4%.
earnings
positive
materiality 0.75
June 18, 2026, 9:22 AM ET
Steel Dynamics guides Q2 2026 EPS $3.51-$3.55, above Q1 $2.78 and prior year $2.01
- Guidance range $3.51-$3.55 per diluted share; Q1 2026 actual $2.78, Q2 2025 actual $2.01.
- Asset write-downs of $16M due to relocating aluminum slab center from Arizona to Mississippi.
- Steel operations expected meaningfully higher; strong demand and metal margin expansion.